NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
Details
- Buyer
- NHS England
- Supplier(s)
37 suppliers
- AVENTIS PHARMA LIMITED
- Abbvie Ltd
- Accord UK Ltd
- Almirall
- Amgen Ltd
- Astra Zeneca UK Limited
- Bayer Public Limited Company
- Celltrion Healthcare United Kingdom Ltd
- Chugai Pharma UK Ltd
- CST Pharma Limited
- Dr Reddy's Laboratories (UK) Ltd
- Eli Lilly and Company Ltd
- Galapagos Biotech Ltd
- GEDEON RICHTER (UK) LIMITED
- GLAXOSMITHKLINE UK LIMITED
- Ipsen
- Janssen Cilag Ltd
- Merck Serono Limited
- MERCK SHARP & DOHME (UK) LIMITED
- Merz
- Mylan
- Napp Pharmaceuticals Ltd
- Neon Healthcare Ltd
- Novartis Pharmaceutical UK Ltd
- Novo Nordisk Ltd
- Organon Pharmaceuticals UK Ltd
- Orifarm UK
- Pfizer Liimted
- Pharmacosmos UK Ltd
- Ranbaxy (UK) Ltd
- Roche Products Ltd
- Sandoz
- Swedish Orphan Biovitrum Ltd (Sobi UK Ltd)
- Teva UK Ltd
- Thornton and Ross
- Vifor Pharma UK Ltd
- Zentiva Pharma UK Ltd
- Value
- £74
- Topic
- Pharmaceutical products
- Published
- 26 February 2024
- Source
- uk:find_a_tender
Tender description
Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024<br/> <br/>Offer reference number: CM/PHR/22/5678<br/> <br/>CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/><br/>CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/><br/>CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months<br/><br/>CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months Lot 1: CM/PHR/22/5678/01 CM/PHR/22/5678/01 - NHS Framework for North of England Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: CM/PHR/22/5678/02 NHS Framework for North of England Branded Medicines - Lot 2. (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: CM/PHR/22/5678/03 CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 4: CM/PHR/22/5678/04 CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Timeline
- Completed: Award date26 January 2024
- Completed: Award published26 February 2024Current notice
About the buyer
NHS England runs the NHS in England, and buys as a central healthcare organisation with its own team of procurement professionals. Much of this procurement flows through framework agreements and the Crown Commercial Service. Seven regional teams support the commissioning of healthcare services across the country. The central commercial function that develops procurement strategy for the whole NHS sits here.
Clinical services are commissioned directly or through the Provider Selection Regime.
Over the past 5 years, most of NHS England's contract awards have been in education and training, health and social work, and IT services.
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
13 similar open tenders
See more open tenders related to Pharmaceutical products.
- Open tender
Generic Drugs - Oral Liquids
- Open tender
Injection Equipment Paraphernalia
- Open tender
NP93827 Seasonal Influenza Vaccine
- Open tender
IMP Manufacture, Labelling and Packaging DPS
- Open tender
CPH037 - Enhanced Services (Pharmacies)
- Open tender
Potassium iodide tablets 2024-2026
Related buyers
Buyers similar to NHS England.
- 510£244.6m
- 448£1.6bn
- 407£112.7m
- 404£2.0bn
- 326£1.2bn
- 322£24.6bn
- 291£1.6bn
- 248£3.1bn
- 156£125.7m
- 150£1.0bn
Finding public sector work shouldn't be hard
Make your next tender search effortless with Stotles. Set up alerts, find decision maker contacts and never miss a good-fit opportunity again.